FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	
vasimigton,	D.C.	20040	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
OI	OMB Number: 3235-0287									
Es	Estimated average burden									
ho	hours per response: 0									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE]						(Ch	Relationship leck all appli X Direct	cable)	g Pers	son(s) to Iss 10% Ov			
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/10/2023							Officer below)	(give title		Other (s below)	pecify	
C/O AEROVATE THERAPEUTICS, INC.			4. If <i>i</i>	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable							
930 WINTER STREET, SUITE M-500												Line) X Form filed by One Reporting Person						
(Street)	AM M	Δ	02451												filed by More		J	
		71			Ru	Rule 10b5-1(c) Transaction Indication						<u></u>						
(City)	(S	tate)	(Zip)		lπ,	Check this box to indicate that a transaction was made pursuant to a contract, instruction or writter satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						plan t	hat is intende	d to				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,		Code (Instr. 5)			Benefic	es ially Following	Form Ily (D) o ollowing (I) (In	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
							Code	٧	Amount	(A) or (D)		Transac	action(s) 3 and 4)			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,		ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		epiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$18.08	07/10/2023			A		25,000		(1)	07	//09/2033	Common Stock	25,000	\$0	25,000		D	

Explanation of Responses:

1. This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on August 10, 2023.

/s/ George A. Eldridge, Attorney-in-Fact

07/11/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.